UK Markets closed

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
41.64+1.63 (+4.07%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close40.01
Open41.44
BidN/A x N/A
AskN/A x N/A
Day's range41.34 - 41.77
52-week range37.88 - 53.86
Volume2,230,996
Avg. volume2,484,891
Market cap287.744B
Beta (5Y monthly)0.31
PE ratio (TTM)18.84
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.24 (3.12%)
Ex-dividend date17 Mar 2022
1y target estN/A
  • Globe Newswire

    Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options

    Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by infection with Human Papillomavirus (HPV). 1Nearly nine out of 10 women who die from cervical cancer live in low- and middle-income countries.2 For patients living in areas with limited healthcare resources, increasing access to screening and decreasing barriers to sample collection are keys to ultimately preventing this disease.Roche’s HPV self sampl

  • Globe Newswire

    Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease

    Crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease For more than a decade Roche has been working in collaboration with Banner Alzheimer’s Institute, the University of Antioquia in Colombia and the National Institute on Aging on this pioneering prevention studyInitial data will be presented at the upcoming Alzheimer's Association International Conference Basel, 16 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHB

  • Business Wire

    Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

    SOUTH SAN FRANCISCO, Calif., June 16, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimer’s Institute, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimer’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-o